Drugs / AP 12009
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00844064 | Jan 2005 → Nov 2011 | colorectal neoplasm, melanoma, pancreatic neoplasm | Isarna Therapeutics GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00431561 | Apr 2003 → Mar 2009 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP 12009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00844064 ↗ |
| Known as | trabedersen | “AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.” NCT00844064 ↗1“10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks” NCT00431561 ↗ |
| Modality | Antisense oligonucleotide | “AP 12009 is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming growth factor-beta2 (TGF-beta2).” NCT00431561 ↗ |
| Route | Other | “10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks” NCT00431561 ↗ |
| Target | TGFB2 | “AP 12009 is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming growth factor-beta2 (TGF-beta2).” NCT00431561 ↗ |